Nolgileucel

Oct. 26, 2026 -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announced that a New Indication Application for sintilimab in combination with Nolgileucel injection (GC101) has been accepted for review by the China National Medical Products Administration (NMPA). The application is proposed to be sintilimab in combination with Nolgileucel Injection (GC101) for the treatment of patients with unresectable or metastatic melanoma whose disease has progressed following at least two lines of prior systemic therapy, including PD-1 antibody therapy. This would be the 11th indication for sintilimab, further consolidating its position as a cornerstone therapy in immuno-oncology (IO). The new indication application is primarily based on the results of the pivotal Phase II clinical study MIZAR-003. MIZAR-003 (NCT04943913) is a pivotal Phase II, multicenter, randomized, open-label, parallel-controlled study designed to evaluate the efficacy and safety of GC101 TIL cell injection with sintilimab support in melanoma patients who have failed or are intolerant to anti-PD-1 antibody therapy. The study results were first presented as an oral Late-Breaking Abstract (LBA 9509) at the 2026 ASCO Annual Meeting in June 2026. As of the data cutoff date of May 12, 2026, the primary endpoint was met. In patients with advanced melanoma who had failed prior anti-PD-1 antibody therapy and had received a median of 2 prior lines of systemic therapy, the median progression-free survival (mPFS) in the experimental arm reached 4.3 months, significantly superior to 1.6 months in the chemotherapy control arm, with a 57% reduction in the risk of disease progression or death (HR=0.43, 95% CI: 0.26–0.68; P=0.0002). Meanwhile, adverse reactions in the experimental arm were manageable. Grade ≥3 adverse reactions were mainly preconditioning-induced hematologic toxicity, and the median AE duration was comparable and rapidly reversible in experimental arm (8 days vs 13 days); most patients recovered without additional intervention. "Treatment options are very limited for patients with advanced, treatment-resistant melanoma," said Professor Guo Jun, Vice President of Peking University Cancer Hospital, Director of the Department of Melanoma and Sarcoma Medical Oncology, and Director of the Department of Urologic Oncology. "For patients whose disease continues to progress after prior PD-1 antibody therapy and multiple lines of systemic treatment, subsequent treatment presents significant challenges, and there is an urgent clinical need for more effective treatment options. The MIZAR-003 study demonstrated positive antitumor activity and a favorable safety profile in this patient population, offering a new treatment option for patients with unresectable or metastatic melanoma who have experienced disease progression following at least two prior systemic therapies, including an anti-PD-1 antibody. We look forward to sintilimab and Nolgileucel bringing further benefits to patients." "We are pleased that the 11th indication application for sintilimab has been accepted for review by the NMPA, with the potential to offer a more effective treatment option for patients with advanced melanoma in China," said Dr. Hui Zhou, Chief R&D Officer of Oncology at Innovent. "This acceptance further consolidates the position of sintilimab as a cornerstone therapy in immuno-oncology. It also marks another milestone for us in advancing the full life-cycle management of this product and continuously maximizing its clinical value." Sintilimab, marketed as TYVYT® (sintilimab injection) in China, is an innovative PD-1 inhibitor co-developed and commercialized by Innovent Biologics and Eli Lilly and Company. Sintilimab is a human immunoglobulin G4 (IgG4) monoclonal antibody that specifically binds to PD-1 molecules on the surface of T cells. By blocking the PD-1/programmed death-ligand 1 (PD-L1) pathway, which contributes to tumor immune tolerance, sintilimab reactivates the antitumor activity of lymphocytes to treat cancer.[i] GC101 was developed using the DeepTIL™ cell enrichment and expansion platform independently developed by Juncell Therapeutics. It is Juncell's most advanced tumor-infiltrating lymphocyte (TIL) therapy program and the world's first TIL therapy that does not require high-intensity lymphodepletion chemotherapy or IL-2 administration. The pivotal Phase II study of GC101 in malignant melanoma has met its primary endpoint, and GC101 has been included in the CSCO Guidelines for the Diagnosis and Treatment of Melanoma (2026 Edition). The study of GC101 for advanced NSCLC is in Phase II, while its use as adjuvant therapy following surgery for glioma is expected to enter a Phase II clinical study. Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 20 products in the market. It has 1 asset under NDA review, 5 assets in phase 3 or pivotal clinical trials, and 20 more molecules in early clinical stage. Innovent has entered into more than 30 strategic partnerships with global players such as Eli Lilly, Roche, Takeda, Pfizer, Sanofi, Incyte, and MD Anderson Cancer Center, representing an aggregate value of over RMB 350 billion. These efforts have set a benchmark for the high-quality outbound internationalization of China's innovative drug industry. Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. Statement: 1) Innovent does not recommend the use of any unapproved drug (s)/indication (s). 2) Ramucirumab (Cyramza®) and selpercatinib (Retsevmo®), pirtobrutinib (Jaypirca®) and abemaciclib (Verzenios®) were developed by Eli Lilly and Company. The content above comes from the network. if any infringement, please contact us to modify.

沿临床证据、技术文献与制造路径，理解一家TIL公司的长期价值。 2026年10月26日，君赛生物宣布，诺吉仑赛注射液（GC101）的新药上市申请获受理，拟联合信迪利单抗用于既往至少两种系统治疗、包含PD-1抗体治疗失败的不可切除或转移性黑色素瘤。七年研发开始进入审评关口，但受理意味着资料进入程序，距离批准与商业使用仍有工作要完成。 公开受理信息转载所列申报企业为上海君赛生物药业有限公司，受理号CXSS2600169。药物申报主体与2019年创立的公司历史分别呈现，药物申请受理也与证券市场的IPO申请属于不同程序。 对投资人，这个节点值得追问的，是一家公司如何把患者自身的细胞做成稳定、可复制交付的药物。君赛的价值线索分布在三个层面：随机对照临床结果、细胞富集和工程化工艺，以及取材到回输之间的制造组织能力。把它们连起来，才能理解GC101之后的平台空间。 公司资料、注册事件与技术文献交叉呈现。从肿瘤里找到细胞，再把它们送回去 TIL是肿瘤浸润淋巴细胞。自体TIL疗法从患者肿瘤组织中取得细胞，在体外培养扩增后回输，希望利用其中具有肿瘤反应性的免疫细胞开展治疗。与货架上的普通药片相比，这条流程更依赖组织取样、细胞状态和每位患者的生产安排。培养出足够数量，也需要兼顾组成与功能。 君赛2019年在上海成立，将平台分别铺向天然TIL扩增、非病毒基因修饰和种子细胞保存。根据公司技术页，DeepTIL支持富集扩增，NovaGMP面向工程化细胞，RiverTIL探索分段生产。三条路径分别处理细胞数量与质量、功能改造和交付时间问题，并不能共用一个临床成功结论。 平台设计与具体产品分开，未将技术页中的优势宣传当作独立对照结论。 GC101的差异化路径包括降低预处理强度、无需IL-2给药。这里需要准确理解：研究仍有低强度预处理，且联合信迪利单抗，不能概括为完全免化疗或只回输细胞。ASCO原摘要与国际登记都描述了组合方案，这也决定了结果应归属于整个治疗策略。资本支持七年，证据开始改变价值锚点 根据 SanoClaw 融资事件库记录，君赛经历多个早期、B系列及C轮节点。复容在最新原稿中提到，2020年投资后又多轮追加；元禾原点、凯泰、怀格、元生等也出现在历史资本网络中。2025年递表报道中的近8亿元是累计融资，不能理解为当日新增的一轮资金。 历史资本记录保留累计与单轮边界，本次没有新增融资金额。 持续资本让细胞工艺、临床网络和制造设施可以并行投入。进入注册阶段后，估值的支点也会变化：从能否稳定制备，逐步转向在明确人群中能否产生可重复获益，再转向潜在获批后的采用与支付。融资提供时间，证据与执行决定这段时间能创造多少价值。读懂随机研究，比记住一个缓解率更重要 SanoClaw收录的管线事件与公司最新更新，呈现了GC101从黑色素瘤向肺癌和脑胶质瘤推进的路径。黑色素瘤的上市申请进度领先；肺癌已有II期登记，脑胶质瘤II期获准后仍需推进研究；GC203则走工程化TIL的独立验证路线。 仅按有明确日期的事件排序，不把资料刷新时间当作临床发生时间。 最有分量的临床线索来自MIZAR-003。公司10月23日ESMO延长随访更新显示，GC101联合方案相对研究者选择化疗，中位无进展生存期为4.37个月对1.61个月，HR为0.44，95%置信区间0.28至0.70；客观缓解率44.0%对8.2%。这是明确研究设计和对照条件下的结果。 延长随访版本独立列示，不与更早摘要混用分析集或百分比。 PFS反映疾病进展或死亡这一复合事件的时间，HR是随访中的相对风险指标，并不表示每名患者延长了固定月份。更重要的是，OS尚未成熟，对照组交叉治疗也会影响后续生存分析。PFS信号支持治疗策略的潜力，总生存获益仍待成熟数据确认。 安全性同样要放回完整流程。公司称延长随访未见新安全信号，但仍有预处理相关血液学毒性。减少高强度处理和IL-2给药，可能降低部分治疗负担，其实际可及性还取决于患者选择、制造等待和医院管理能力，不能直接外推为没有严重不良反应或适合所有实体瘤。 直接核对的国际登记按最近公开更新日期倒序；人数为计划口径。 SanoClaw国内临床登记逐条列出，不与国际登记重复加总为独立研究数。 根据 SanoClaw 临床试验读模型，国内已收录从晚期实体瘤I期，到黑色素瘤II期、肺癌I期及GC203I期的多条登记。国际登记还补充了肺癌II期。它们把产品演进落实到具体研究设计，也提醒读者：登记计划人数、实际入组和终点分析集各有含义，不同更新版本不应拼成一份看似统一的实时结果。六十三条文献，展开细胞药的工艺层次 根据 SanoClaw 以申请人链路呈现的技术资产线索，本次采集到63条公开或公告文献，保留上海君赛历史名称、股份公司及药业公司的共同申请记录。样本包含A/B版本、PCT与分案线索，不能据此计算63项独立发明，更不能直接替代现时有效权利清单。 高信号记录涉及富集、电转与保存，完整样本可在下方展开。 CN119643843B结合活化、抑制等标志物鉴定和富集肿瘤特异性免疫细胞。它回应了一个关键问题：扩增之后的细胞，有多少真正与肿瘤反应相关？这一方向将质量判断前移到制备流程。原文明确为分案申请，同题名或同族文献不能简单累加为完全独立的技术壁垒。 CN121699862A涉及电转前处理试剂，关注导入外源基因后的细胞存活与表达。这对工程化细胞工艺具有意义，但GC101是天然TIL，不能把每一项基因修饰申请都当成其现行工艺。专利提出的实验方案与实际注册产品的实施、效果和保护范围，需要分别判断。 查看全部63条技术文献（时间倒序） 逐条列出文献号、名称、申请人及申请日期；原文索引见文末。 逐条列出文献号、名称、申请人及申请日期；原文索引见文末。 逐条列出文献号、名称、申请人及申请日期；原文索引见文末。 逐条列出文献号、名称、申请人及申请日期；原文索引见文末。 逐条列出文献号、名称、申请人及申请日期；原文索引见文末。 逐条列出文献号、名称、申请人及申请日期；原文索引见文末。 逐条列出文献号、名称、申请人及申请日期；原文索引见文末。 逐条列出文献号、名称、申请人及申请日期；原文索引见文末。 逐条列出文献号、名称、申请人及申请日期；原文索引见文末。 逐条列出文献号、名称、申请人及申请日期；原文索引见文末。 逐条列出文献号、名称、申请人及申请日期；原文索引见文末。 其余文献铺开培养基、种子细胞、冻存复苏、膜结合细胞因子、辅助受体和信号转换等方向。整体上可以看到公司在扩增、筛选、保存和改造多个环节布局。平台空间来自这些方法未来能否转成可验证、可制造的新产品，当前一款产品的进展不能自动兑现整个文献组合的价值。最后一段路，是制造与临床网络一起走 研究协作保留具体角色，未将研究中心或联合用药变成商业客户与BD交易。 多中心试验提供跨医院积累证据的机会。对自体细胞药，这个网络也要求取材、运输、生产、放行、回输和长期追踪协同运行。同一款产品能否在不同中心稳定完成流程，直接影响可治疗患者数量与单位交付效率。临床合作是起点，商业采用仍要完成注册、培训和支付等环节。 历史财务数据来自港交所申请版本，不视为当前经营快照。 2026年6月申请版本列示，2025年研发成本约1.149亿元，其中GC101约8341万元、占72.6%。这体现核心产品的资源集中度，也意味着后续管线与商业准备仍会持续需要资金。历史费用不能直接换算当前现金跑道或未来患者价格，获批后的制造成功率、交付周期和实际支付能力，还将共同影响经营回报。 君赛七年的吸引力，在于细胞工艺、随机临床与多中心执行已经连接成一条产品路径。申请受理把GC101带到新的审评关口；其后的价值，将由更成熟的随访、可重复的制造和真实患者可及性逐步兑现。对于投资人，这是一家开始接受产品级与经营级双重检验的平台公司。 主要公开来源 GC101上市申请受理，公司消息及复容投资转发 ESMO 2026延长随访，公司原文 ASCO LBA9509研究原摘要 MIZAR-003国际登记 GC101肺癌II期国际登记 公司技术平台 公司临床研究页面 公司管线新闻 2026年6月港交所申请版本 本文基于SanoClaw 数据生成。 国内首个专注于一级市场的AI Agent 决策助手来了！ SanoClaw 是国内首个面向医疗与硬科技投资人的 AI 投研工作台，围绕投研判断，系统整合融资事件、投资方网络、公司画像、产品与管线进展、专利与技术资产、临床试验、学术文献、合作事件、商业化线索、竞品公司、赛道趋势和估值参照等多维数据。通过多数据维度，SanoClaw 可以帮助投资人快速还原一家公司的发展路径，识别关键融资拐点、技术壁垒、产业资源、研发进展、市场位置和潜在风险，让项目判断建立在更完整、更可追溯的证据链之上。